SEBI Registration NO.---- INA000001530 Investment in stock and commodity market are subject to market risk. Please do not trade on those tips which are not provided through SMS or messenger.

Top Stocks to be Focused for 8 Dec 2016

Top Stocks to be Focused for 8 Dec 2016

Crompton Greaves: The company reported a consolidated net loss of Rs 10.41 crore in quarter ended on September 30, 2016. The group had a net profit of Rs 10.58 crore for the quarter ended September 30, 2015.

Divi’s Laboratories: Drug firm Divi’s Laboratories on Wednesday said the US health regulator has made five observations after inspection of its manufacturing plant at Visakhapatnam in Andhra Pradesh.

Tata Steel, Adani Ports: A Tata Steel subsidiary has sold its tug services firm to Adani Ports and Special Economic Zone (APSEZ) for Rs 106 crore in an all-cash deal.

Polaris: IT company Polaris Consulting & Services posted a decline of 27.88 per cent in consolidated net profit at Rs 41.14 crore for the three-month period ended on September 30, 2016, and announced that its CEO Jitin Goyal has quit.

IOC, BPCLBSE 0.81 %, HPCL: Indian Oil Corporation, Bharat Petroleum CorporationBSE 0.81 % and Hindustan PetroleumBSE 1.06 % Corp on Wednesday signed a pact to build India’s biggest oil refinery at a cost of $30 billion on the west coast.

Results Today: Steel Authority ofBSE 3.37 % India, MMTC, Finolex IndustriesBSE 0.24 % and Claris Life Sciences will announce their financial results for the quarter ended September 30, 2016 on Thursday.

Prestige Estates: For the quarter ended September 30, 2016, the company reported a consolidated net profit of Rs 64.51 crore, down 58.24 per cent, against Rs 154.47 crore in the corresponding quarter last year.

Sun Pharmaceutical: Sun Pharmaceutical said the United States health regulator has issued an observation letter after the completion of its Halol facility inspection.

Pharma companies: US President-elect Donald Trump in an interview with the Time magazine said he would bring down prescription drug prices. Domestic drug makers generate a significant percentage of their revenues from the US market.

error: Content is protected !!